The company’s top-line performance remained resilient, with revenue climbing to ¥15.90 billion from ¥13.00 billion in the corresponding quarter last year. This growth was reflected in the operating profit, which surged to ¥2.79 billion, more than doubling the ¥1.25 billion reported in the previous period.

Operational Gains vs. Bottom-Line Pressure

While the company saw expanded margins at the operational level, the net result was weighed down by factors that offset the top-line growth. Pretax profit rose to ¥2.65 billion, yet the final profit available to shareholders diminished significantly. As a result, earnings per share dropped to ¥13.28, a steep decline from the ¥40.75 recorded in the prior year.

The figures, prepared under Japanese accounting standards, suggest a period of increased non-operating costs or tax adjustments that hampered the company’s bottom line. Key financial highlights for the quarter include:

• Revenue increased by approximately 22% year-on-year.
• Operating profit grew by 123% compared to the 2024 fiscal first quarter.
• Net profit margin saw a significant year-on-year contraction.

Fuji Pharma's results highlight a dichotomy between robust market demand and the challenges of maintaining net profitability in the current fiscal environment.